NDA 218579 · Provepharm Sas
Zyogreen
Indocyanine Green · Intravenous, Interstitial · Diagnostic Dye
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Jul 10, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
249
28 Phase 3, 43 recruiting
FAERS reports
108
102 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2026.
ZYOGREEN is an optical imaging agent indicated for: Fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures, in adults and pediatric patients ( 1.1 ) Fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older ( 1.2 ) Fluorescence imaging of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer ( 1.3 ) Ophthalmic angiography in adults and pediatric patients ( 1.4 ) 1.1 Visualization of Vessels, Blood Flow and Tissue Perfusion ZYOGREEN is indicated for fluorescence imaging of vessels (micro- and macro-vasculature), blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries, including general minimally invasive surgical procedures in adults and pediatric patients. 1.2 Visualization of Extrahepatic Biliary Ducts ZYOGREEN is indicated for fluorescence imaging of extrahepatic biliary ducts in adults and pediatric patients from birth to less than 1 year of age and 6 years of age and older. 1.3 Lymphatic Mapping of Cervical and Uterine Cancer ZYOGREEN is indicated for fluorescence imaging of lymph nodes and delineation of lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer for which this procedure is a component of intraoperative management. 1.4 Ophthalmic Angiography ZYOGREEN is indicated for use in ophthalmic angiography in adults and pediatric patients.
Mechanism: When bound to proteins in plasma or in lymph fluid, indocyanine green absorbs light in the near-infrared region with peak absorption at 805 nm and emits fluorescence (light) at a slightly longer wavelength, with peak emission at 830 nm. Fluorescence imaging devices provide external energy as near infrared light for indocyanine green to absorb, resulting in excitation of the indocyanine green, and the emitted light (fluorescence) is transferred from the field of view to an image on a monitor. These optical properties of indocyanine green are utilized in fluorescence imaging of the micro- and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZYOGREEN · INDOCYANINE GREEN 25MG/10ML (2.5MG/ML) · SOLUTION, INTRAVENOUS, INTERSTITIAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Indocyanine Green" as an intervention, any sponsor and status, largest first.
- The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal SurgeryPivotal-lookingNot yet recruiting
Vadim KuznetsovResearch network
NCT06845306 · 1,268 participants (planned) · Start Jun 1, 2025 · Primary completion Jul 1, 2026
Drug: ICG-guided bowel perfusion assessment · For: Colo-rectal Cancer; Colonic Neoplasms Malignant
Sites: Vsevolozhsk District, Russia
Isabelle HenskensAcademic, hospital or other
NCT07146295 · 1,150 participants (planned) · Start Apr 18, 2025 · Primary completion Feb 2027
Drug: Technetium (99mTc); Indocyanine Green · For: Breast Cancer; Sentinel Lymph Node Biopsy (SLNB); Sentinel Lymph Node Detection and 6 more
Sites: Alkmaar, Netherlands; Hengelo, Netherlands; Hoofddorp, Netherlands · 7 sites in all
- Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic LeakagePivotal-lookingStatus unknown
Centre Hospitalier Universitaire de BesanconAcademic, hospital or other
NCT05168839 · 1,010 participants (planned) · Start Sep 26, 2022 · Primary completion Oct 31, 2025
Drug: FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG). · For: Colorectal Cancer
Sites: Amiens, France; Annecy, France; Besançon, France · 32 sites in all
- Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage RatesPivotal-lookingStatus unknown
Leiden University Medical CenterAcademic, hospital or other
NCT04712032 · 978 participants (planned) · Start Jul 1, 2020 · Primary completion Jul 1, 2022
Drug: ICG-guided bowel perfusion assessment · For: Colo-rectal Cancer; Crohn Disease; Resectable Colorectal Carcinoma
Sites: Leiden, Netherlands
- Fluorescence for Sentinel Lymph Node Identification in Cancer SurgeryPivotal-lookingCompleted
Institut de Cancérologie de LorraineAcademic, hospital or other
NCT02997553 · 744 participants · Start Nov 29, 2017 · Primary completion Sep 19, 2022
Drug: Indocyanine green; Technetium99 · For: Breast Carcinoma; Head and Neck Cancer; Melanoma (Skin) and 7 more
Sites: Vandœuvre-lès-Nancy, France
- NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG TechniquePivotal-lookingNot yet recruiting
The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAcademic, hospital or other
NCT06610071 · 592 participants (planned) · Start Oct 30, 2024 · Primary completion Dec 2028
Drug: ICG administration; ICG administration and 2 more · For: Dermatofibrosarcoma Protuberans (DFSP); Skin Squamous Cell Carcinoma
University of PennsylvaniaAcademic, hospital or other
NCT04723810 · 500 participants (planned) · Start Aug 14, 2024 · Primary completion Jan 14, 2027
Drug: Indocyanine Green · For: Tumor, Solid
Sites: Philadelphia, Pennsylvania
- Use of Indocyanine Green in Acute CholecystitisPivotal-lookingStatus unknown
Corporacion Parc TauliAcademic, hospital or other
NCT05709548 · 440 participants (planned) · Start Mar 15, 2023 · Primary completion Dec 2025
Drug: Indocyanine green · For: Acute Cholecystitis; Bile Duct Injury
Sites: Sabadell, Spain; Vic, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- palpitations10
- urticaria9
- dyspnoea8
- haemangioma congenital8
- low birth weight baby8
- patent ductus arteriosus8
- disease progression7
- liver function test increased7
- off label use7
- visual acuity reduced7
- abdominal pain6
- dizziness6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 5 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 7 |
| 2018 | 17 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 13 |
| 2023 | 11 |
| 2024 | 6 |
| 2025 | 11 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Indocyanine Green Videoangiography in Aneurysm Surgery: Systematic Review and Meta-Analysis.
Riva M, Amin-Hanjani S, Giussani C, et al. · Neurosurgery 2018 · Meta-Analysis, Systematic Review
- Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage: A Randomized Clinical Trial.
Rinne JKA, Huhta H, Pinta T, et al. · JAMA Surg 2025 · Multicenter Study, Randomized Controlled Trial
- Indocyanine green fluorescence angiography for anastomotic perfusion assessment in colorectal surgery: a systematic review with meta-analysis, meta-regression, and trial sequential analyses.
Ryan ÉJ, Ryan OK, Corrigan N, et al. · Lancet Gastroenterol Hepatol 2026 · Systematic Review, Meta-Analysis
- European Association for Endoscopic Surgery (EAES) consensus on Indocyanine Green (ICG) fluorescence-guided surgery.
Cassinotti E, Al-Taher M, Antoniou SA, et al. · Surg Endosc 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial.
Faber RA, Meijer RPJ, Droogh DHM, et al. · Lancet Gastroenterol Hepatol 2024 · Multicenter Study, Randomized Controlled Trial
- Indocyanine green fluorescence for parathyroid gland identification and function prediction: Systematic review and meta-analysis.
Kim DH, Kim SH, Jung J, et al. · Head Neck 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Provepharm Sas
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.